SAINT LAURENT, Quebec, Nov. 7, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) (“IntelGenx”) today announced that the U.S. Food and Drug Administration (“FDA”) has revised the CPI-300 Prescription Drug User Fee Act (“PDUFA”) date to November 10th, 2011 from their previous guidance of November 13th, 2011. CPI-300 is a novel, high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL®.
